KRAS and non-small cell lung carcinoma: Together, we propose that in K-Ras-driven NSCLC and possibly PDAC, elevation of cellular antioxidants prevents the oxidative modification of the His95 residue of oncogenic mutant K-Ras, promoting stable K-Ras/PM binding, and thereby the MAPK signaling, which results in elevated cell proliferation.